Adis Journals
APA-DR-DE-002 Clinical Considerations Table 08.09.20.PNG (37.68 kB)

Apalutamide: A Review in Metastatic Castration-Sensitive Prostate Cancer

Download (37.68 kB)
online resource
posted on 2020-09-08, 03:01 authored by Sheridan M. Hoy
Funding The preparation of this review was not supported by any external funding.
Authorship and Conflict of interest Sheridan Hoy is a salaried employee of Adis International Ltd/Springer Nature and declares no relevant conflicts of interest. All authors contributed to the review and are responsible for the article content.
Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability Not applicable.

Additional information about this Adis Drug Review can be found here.

Apalutamide (Erleada® ) is an oral selective androgen receptor (AR) inhibitor that binds directly to the ligand-binding domain of the AR. It is approved in the EU and the USA for the treatment of adult men with metastatic castration-sensitive prostate cancer (mCSPC). In a multinational, phase III study (TITAN) in this patient population, the addition of apalutamide (240 mg once daily) to androgen deprivation therapy (ADT) significantly improved median radiographic progression-free survival (rPFS), median overall survival (OS) and the median time to cytotoxic chemotherapy, while maintaining health-related quality of life (HR-QOL) and not substantially differing from placebo plus ADT in safety. Although mature OS data are awaited with interest, the addition of apalutamide to ADT extends the treatment options available for standard of care in adult men with mCSPC.

© Springer Nature Switzerland AG 2020


Usage metrics



    Ref. manager